This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Houghton, J. A. Articles by Houghton, P. J. Search for Related Content PubMed Articles by Houghton, J. A. Articles by Houghton, P. J.

Relationship between Dose Rate of [6RS]Leucovorin Administration, Plasma Concentrations of Reduced Folates, and Pools of 5,10-Methylenetetrahydrofolates and Tetrahydrofolates in Human Colon Adenocarcinoma Xenografts¹

Laboratories for Developmental Therapeutics, Department of Biochemical and Clinical Pharmacology [J. A. H., L. G. W., P. J. C., P. J. H.], and Department of Pharmacokinetics [J. H. R., D. C. M., I. W. W., P. J.], St. Jude Children's Research Hospital, Memphis, Tennessee 38101, and Department of Pediatrics [S. S. N. d. G.], University Hospital, P. O. Box 30-001, 9700 RB Groningen, The Netherlands

[6RS]Leucovorin (5-formyltetrahydrofolate; 5-CHO-H₄PteGlu) administered in different regimens in combination with 5-fluorouracil (FUra) has increased the response rates to FUra in patients with colon adenocarcinoma. Using preclinical models of human colon adenocarcinomas as xenografts in immune-deprived mice, the effect of the rate of administration of racemic [6RS]leucovorin on the concentration-time profile of reduced folates in plasma, size of intratumor pools of 5,10-methylenetetrahydrofolates (CH₂-H₄PteGlu_n) and tetrahydrofolates (H₄PteGlu_n), and the distribution of their polyglutamate species have been examined.

Bolus injection i.v., or 4-h or 24-h infusion of [6RS]leucovorin (500 mg/m²) yielded similar concentration profiles of the biologically active [6S] and inactive [6R] isomers of 5-CHO-H₄-PteGlu and 5-methyltetrahydrofolate (5-CH₃-H₄PteGlu) in mouse plasma to those previously reported in humans, but with more rapid elimination half-lives (t_v2 = 11 to 16 min, 23 to 41 min, and 30 to 35 min, respectively). Thus, reduced folates remained elevated in plasma during the period of [6RS]leucovorin administration. In HxELC₂ and HxGC₃ tumors, pools of CH₂-H₄PteGlu_n and H₄PteGlu_n were increased from 350% to 700% of control, but only during [6RS]leucovorin infusion. Intracellular levels subsequently declined rapidly, similar to the loss of reduced folates from plasma. Increasing the rate of [6RS]leucovorin delivery by decreasing the time for administration from a 24-h to a 4-h infusion did not further increase the intratumor pools of CH₂-H₄PteGlu_n and H₄PteGlu_n, suggesting saturation in the cellular metabolism of [6RS]leucovorin.

In HxGC₃ tumors, CH₂-H₄PteGlu_4–5 were elevated more rapidly than in line HxELC₂, which accumulated predominantly a shorter chain length species following i.v. bolus injection. During the 4-h infusion schedule, di- and triglutamate species in particular accumulated in both tumors with no elevation in CH₂-H₄PteGlu₅ until the infusion was discontinued, when this species increased as the shorter chain length forms were declining. However, during the 24-h infusion of [6RS]leucovorin, CH₂-H₄PteGlu_3–5 were elevated in tumors. Since these species have been reported to increase the binding affinity of [6-³H]5-fluorodeoxyuridine monophosphate ([6-³H]FdUMP) to thymidylate synthase, and intratumor pools of CH₂-H₄PteGlu_n and H₄PteGlu_n were elevated during the 24-h infusion of [6RS]leucovorin, this was considered to be the preferred schedule for administration. When FUra (6.25 to 25 mg/kg) was administered 3 h into a 24-h infusion of [6RS]leucovorin (500 mg/m²) in tumor-bearing mice, potentiation of thymidylate synthase inhibition in comparison with FUra administered alone was observed. These studies raise important questions regarding the effect of (a) dose of [6RS]-leucovorin, (b) frequency of administration, (c) utility of 5-CH₃-H₄PteGlu, and (d) [6R]5-CHO-H₄PteGlu on influencing intratumor pools of CH₂-H₄PteGlu_n and H₄PteGlu_n, the inhibition of thymidylate synthase by FUra, and FUra cytotoxicity in colon tumors under the in situ conditions of tumor growth.

¹ Supported by National Cancer Institute Awards CA32613, CA23099, and Cancer Center Support (CORE) Grant CA21765; Center of Excellence Award, University of Tennessee; and American Lebanese Syrian Associated Charities.

² To whom requests for reprints should be addressed.

Received 8/ 4/89. Revised 3/ 8/90.

This article has been cited by other articles:

				I. M. Hennig, J. D. Naik, S. Brown, A. Szubert, D. A. Anthoney, D. P. Jackson, A. M. Melcher, S. M. Crawford, C. Bradley, J. M.B. Brown, et al. Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin J. Clin. Oncol., July 10, 2008; 26(20): 3411 - 3417. [Abstract] [Full Text] [PDF]

				Y. Matsumura, K. Haruyama, T. Hamaguchi, K. Shirao, K. Muro, Y. Yamada, Y. Shimada, and K. Sugano Effect of a 3-hour Interval Between Methotrexate and 5-Fluorouracil in the Treatment of Metastatic Colorectal Cancer Jpn. J. Clin. Oncol., January 1, 2002; 32(1): 9 - 13. [Abstract] [Full Text] [PDF]

				M. E Royce, W. McGarry, B. Bready, S. R. Dakhil, R. J. Belt, J. W. Goodwin, R. Gray, P. M. Hoff, R. Winn, and R. Pazdur Sequential Biochemical Modulation of Fluorouracil With Folinic Acid, N-Phosphonacetyl-L-Aspartic Acid, and Interferon Alfa-2a in Advanced Colorectal Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3276 - 3282. [Abstract] [Full Text] [PDF]

				B. van Triest, H. M. Pinedo, Y. van Hensbergen, K. Smid, F. Telleman, P. S. Schoenmakers, C. L. van der Wilt, J. A. M. van Laar, P. Noordhuis, G. Jansen, et al. Thymidylate Synthase Level as the Main Predictive Parameter for Sensitivity to 5-Fluorouracil, but not for Folate-based Thymidylate Synthase Inhibitors, in 13 Nonselected Colon Cancer Cell Lines Clin. Cancer Res., March 1, 1999; 5(3): 643 - 654. [Abstract] [Full Text] [PDF]

				J. Jolivet, A. Dayan, M. Beauchemin, D. Chahla, A. Mamo, and R. Bertrand Biochemical and Molecular Studies of Human Methenyltetrahydrofolate Synthetase Oncologist, August 1, 1996; 1(4): 248 - 253. [Abstract] [Full Text] [PDF]

				J Jolivet, A Dayan, M Beauchemin, D Chahla, A Mamo, and R Bertrand Biochemical and molecular studies of human methenyltetrahydrofolate synthetase Stem Cells, January 1, 1996; 14(1): 33 - 40. [Abstract]